Moody Aldrich Partners LLC Has $5.37 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Moody Aldrich Partners LLC lessened its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 119,287 shares of the company’s stock after selling 14,928 shares during the quarter. Moody Aldrich Partners LLC owned approximately 0.20% of Protagonist Therapeutics worth $5,368,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Farallon Capital Management LLC grew its stake in Protagonist Therapeutics by 1.8% in the second quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company’s stock valued at $202,383,000 after purchasing an additional 101,800 shares in the last quarter. Vanguard Group Inc. grew its stake in Protagonist Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock valued at $92,373,000 after purchasing an additional 39,055 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 27.6% during the 2nd quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company’s stock worth $43,962,000 after acquiring an additional 274,412 shares during the period. Millennium Management LLC boosted its stake in shares of Protagonist Therapeutics by 2,135.6% during the 2nd quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock worth $33,205,000 after acquiring an additional 915,418 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Protagonist Therapeutics by 813.4% during the 2nd quarter. Renaissance Technologies LLC now owns 297,467 shares of the company’s stock worth $10,307,000 after acquiring an additional 264,900 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock traded up $0.31 during trading on Thursday, reaching $46.90. 34,250 shares of the company’s stock were exchanged, compared to its average volume of 746,676. The company has a market cap of $2.76 billion, a P/E ratio of 17.78 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 1-year low of $13.72 and a 1-year high of $48.32. The firm’s 50-day moving average price is $44.27 and its 200 day moving average price is $36.39.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). The firm had revenue of $4.17 million for the quarter, compared to the consensus estimate of $40.00 million. As a group, equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.32 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on PTGX. HC Wainwright lifted their target price on Protagonist Therapeutics from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. JPMorgan Chase & Co. boosted their price target on Protagonist Therapeutics from $39.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. StockNews.com upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. BTIG Research boosted their price target on Protagonist Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Finally, TD Cowen raised Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $49.86.

Insider Activity at Protagonist Therapeutics

In related news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $540,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Asif Ali sold 14,203 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $44.49, for a total value of $631,891.47. Following the completion of the sale, the chief financial officer now directly owns 34,960 shares of the company’s stock, valued at $1,555,370.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William D. Waddill sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $540,000. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.40% of the stock is owned by corporate insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.